3 results
Primary objectives: Part A: Generate an airway gene expression signature for itepekimab treatment using RNA sequencing in former smokers with COPDPart B: Validate the airway gene expression signature from Part A in former smokers with COPD in Part…
Primary objectivePrimary population (former smokers cohort):- Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD.Secondary…
The primary objective of this study is to evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI).